PhaseBio Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapies for serious cardiovascular diseases. The company's lead program was a ticagrelor reversal agent leveraging its proprietary ELP (elastin-like polypeptide) drug delivery platform. PhaseBio filed for Chapter 11 bankruptcy protection in October 2022 after its lead cardiovascular drug candidate failed to meet its primary endpoint in a pivotal clinical trial.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountOct 2018
Sep 2018
Mar 2015
Jan 2010
Sep 2006
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
